BridgeBio Pharma Company Leadership

BridgeBio Pharma's latest congressional trading

BridgeBio Pharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.4348) % which means that it has lost $0.4348 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.8967) %, meaning that it created substantial loss on money invested by shareholders. BridgeBio Pharma's management efficiency ratios could be used to measure how well BridgeBio Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of February 2026, Return On Equity is likely to grow to 0.34, while Return On Tangible Assets are likely to drop (0.72). At this time, BridgeBio Pharma's Non Current Assets Total are very stable compared to the past year. As of the 17th of February 2026, Other Assets is likely to grow to about 170 M, while Total Assets are likely to drop about 687.5 M. As of the 17th of February 2026, Common Stock Shares Outstanding is likely to drop to about 144.2 M. In addition to that, Net Loss is likely to drop to about (454.7 M)BridgeBio Pharma holds a total of 191.63 Million outstanding shares. The majority of BridgeBio Pharma outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in BridgeBio Pharma to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in BridgeBio Pharma. Please pay attention to any change in the institutional holdings of BridgeBio Pharma as this could imply that something significant has changed or is about to change at the company. Also note that nearly six million nine hundred seventy-five thousand two hundred twenty-two invesors are currently shorting BridgeBio Pharma expressing very little confidence in its future performance. Some institutional investors establish a significant position in stocks such as BridgeBio Pharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of BridgeBio Pharma, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

BridgeBio Pharma Workforce Comparison

BridgeBio Pharma Profit Margins

The company has Profit Margin (PM) of (2.25) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.13.

BridgeBio Pharma Insider Trading History

BridgeBio Pharma Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as BridgeBio Pharma often depends on how effective the management is. BridgeBio Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BridgeBio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BridgeBio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

BridgeBio Pharma's market price often diverges from its book value, the accounting figure shown on BridgeBio's balance sheet. Smart investors calculate BridgeBio Pharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since BridgeBio Pharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.

It's important to distinguish between BridgeBio Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BridgeBio Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.